Kidney repair cells tested in diabetes patients for first time

NCT ID NCT07275788

Recruiting now Disease control Sponsor: Regend Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new treatment called REGEND003, made from human kidney progenitor cells, in 15 people with type 2 diabetes and chronic kidney disease. The main goal is to check if the treatment is safe and tolerable. Participants will receive either the cell therapy or a placebo via injection into the kidney, and researchers will monitor for side effects and signs of inflammation or kidney function change.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGEND003 (human kidney progenitor cells)
What this could lead to: If safe and effective, this could point toward a new way to repair kidney damage in people with diabetes and chronic kidney disease.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not effectiveness. The cells may not work as hoped, and there are risks from the injection procedure and the cells themselves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM) AND CHRONIC KIDNEY DISEASE (CKD)

Contacts and locations

Locations

Shanghai Tongji Hospital
RECRUITING

Shanghai, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.